These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32784934)

  • 41. Risk of secondary malignancy (including breast) in patients with mismatch-repair protein deficiency.
    Clay MR; Allison KH; Folkins AK; Longacre TA
    Am J Surg Pathol; 2014 Nov; 38(11):1494-500. PubMed ID: 24921635
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Commentary on "Risks of primary extracolonic cancers following colorectal cancer in Lynch syndrome." Win AK, Lindor NM, Young JP, Macrae FA, Young GP, Williamson E, Parry S, Goldblatt J, Lipton L, Winship I, Leggett B, Tucker KM, Giles GG, Buchanan DD, Clendenning M, Rosty C, Arnold J, Levine AJ, Haile RW, Gallinger S, Le Marchand L, Newcomb PA, Hopper JL, Jenkins MA, Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, Melbourne School of Population Health, The University of Melbourne, Victoria, Australia: J Natl Cancer Inst 2012;104(18):1363-72 [Epub 2012 Aug 28].
    See WA
    Urol Oncol; 2013 Jul; 31(5):716. PubMed ID: 23796201
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Testing strategies to reduce morbidity and mortality from Lynch syndrome.
    Keränen A; Ghazi S; Carlson J; Papadogiannakis N; Lagerstedt-Robinson K; Lindblom A
    Scand J Gastroenterol; 2018 Dec; 53(12):1535-1540. PubMed ID: 30572730
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comprehensive Constitutional Genetic and Epigenetic Characterization of Lynch-Like Individuals.
    Dámaso E; González-Acosta M; Vargas-Parra G; Navarro M; Balmaña J; Ramon Y Cajal T; Tuset N; Thompson BA; Marín F; Fernández A; Gómez C; Velasco À; Solanes A; Iglesias S; Urgel G; López C; Del Valle J; Campos O; Santacana M; Matias-Guiu X; Lázaro C; Valle L; Brunet J; Pineda M; Capellá G
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32635641
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinicopathologic and Molecular Characteristics of Synchronous Colorectal Carcinoma With Mismatch Repair Deficiency.
    Nakano K; Yamamoto H; Fujiwara M; Koga Y; Tsuruta S; Ihara E; Oki E; Nakamura M; Ogawa Y; Oda Y
    Am J Surg Pathol; 2018 Feb; 42(2):172-182. PubMed ID: 28877066
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Histology of colorectal adenocarcinoma with double somatic mismatch-repair mutations is indistinguishable from those caused by Lynch syndrome.
    Hemminger JA; Pearlman R; Haraldsdottir S; Knight D; Jonasson JG; Pritchard CC; Hampel H; Frankel WL
    Hum Pathol; 2018 Aug; 78():125-130. PubMed ID: 29723603
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk of Different Cancers Among First-degree Relatives of Pancreatic Cancer Patients: Influence of Probands' Susceptibility Gene Mutation Status.
    Antwi SO; Fagan SE; Chaffee KG; Bamlet WR; Hu C; Polley EC; Hart SN; Shimelis H; Lilyquist J; Gnanaolivu RD; McWilliams RR; Oberg AL; Couch FJ; Petersen GM
    J Natl Cancer Inst; 2019 Mar; 111(3):264-271. PubMed ID: 29982661
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: are all mutations equal?
    Maccaroni E; Bracci R; Giampieri R; Bianchi F; Belvederesi L; Brugiati C; Pagliaretta S; Del Prete M; Scartozzi M; Cascinu S
    Oncotarget; 2015 Nov; 6(36):38737-48. PubMed ID: 26485756
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A modified screening strategy for Lynch syndrome among MLH1-deficient CRCs: Analysis from consecutive Chinese patients in a single center.
    Wang W; Ying J; Shi S; Ye Q; Zou S; Dong L; Lyu N
    Transl Oncol; 2021 May; 14(5):101049. PubMed ID: 33676177
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Contribution of rare germline copy number variations and common susceptibility loci in Lynch syndrome patients negative for mutations in the mismatch repair genes.
    Villacis RA; Miranda PM; Gomy I; Santos EM; Carraro DM; Achatz MI; Rossi BM; Rogatto SR
    Int J Cancer; 2016 Apr; 138(8):1928-35. PubMed ID: 26620301
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systematic immunohistochemical screening for Lynch syndrome in colorectal cancer: a single centre experience of 486 patients.
    Zumstein V; Vinzens F; Zettl A; Heinimann K; Koeberle D; von Flüe M; Bolli M
    Swiss Med Wkly; 2016; 146():w14315. PubMed ID: 27152634
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identifying Lynch Syndrome in Women Presenting With Endometrial Carcinoma Under the Age of 50 Years.
    Anagnostopoulos A; McKay VH; Cooper I; Campbell F; Greenhalgh L; Kirwan J
    Int J Gynecol Cancer; 2017 Jun; 27(5):931-937. PubMed ID: 28498244
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumor development in Japanese patients with Lynch syndrome.
    Saita C; Yamaguchi T; Horiguchi SI; Yamada R; Takao M; Iijima T; Wakaume R; Aruga T; Tabata T; Koizumi K
    PLoS One; 2018; 13(4):e0195572. PubMed ID: 29672549
    [TBL] [Abstract][Full Text] [Related]  

  • 55. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome.
    Vasen HF; Abdirahman M; Brohet R; Langers AM; Kleibeuker JH; van Kouwen M; Koornstra JJ; Boot H; Cats A; Dekker E; Sanduleanu S; Poley JW; Hardwick JC; de Vos Tot Nederveen Cappel WH; van der Meulen-de Jong AE; Tan TG; Jacobs MA; Mohamed FL; de Boer SY; van de Meeberg PC; Verhulst ML; Salemans JM; van Bentem N; Westerveld BD; Vecht J; Nagengast FM
    Gastroenterology; 2010 Jun; 138(7):2300-6. PubMed ID: 20206180
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetic Testing for Hereditary Nonpolyposis Colorectal Cancer (HNPCC).
    Nallamilli BRR; Hegde M
    Curr Protoc Hum Genet; 2017 Jul; 94():10.12.1-10.12.23. PubMed ID: 28696559
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
    Jin W; Wang LQ; Liu Y; Liu AJ
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
    [No Abstract]   [Full Text] [Related]  

  • 59. No Evidence of Increased Risk of Breast Cancer in Women With Lynch Syndrome Identified by Multigene Panel Testing.
    Stoll J; Rosenthal E; Cummings S; Willmott J; Bernhisel R; Kupfer SS
    JCO Precis Oncol; 2020 Nov; 4():51-60. PubMed ID: 35050728
    [TBL] [Abstract][Full Text] [Related]  

  • 60. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
    Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
    Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.